# Nano-formulated pomegranate extracts with dual cytotoxic and antimicrobial activity: molecular docking and mechanistic insights into leukemia cell targeting

**Authors:** Naglaa M. Hamdy, Ahmed Ismail, Hoda S. Sherkawy, Ayman S. Yassin, Mohamed M. Amin, Hanan M. El-Tantawy, Abdulrahman M. Saleh, Nashwa El-Khazragy

PMC · DOI: 10.1186/s12906-026-05291-9 · BMC Complementary Medicine and Therapies · 2026-02-26

## TL;DR

Nano-formulated pomegranate peel extract shows strong cancer cell-killing and antibacterial effects, with improved effectiveness due to better delivery and impact on cell death pathways.

## Contribution

A nano-formulated pomegranate peel extract with enhanced dual cytotoxic and antimicrobial activity is introduced, along with mechanistic insights into its action on leukemia cells.

## Key findings

- Nano-encapsulation increased the extract's cytotoxic efficacy, reducing the IC₅₀ from 1.48 µg/mL to 0.19 µg/mL.
- The nano-formulated extract induced apoptosis and cell cycle arrest in THP-1 leukemia cells.
- n-PPE-EA downregulated BCL2, PI3K, and CDK8 gene expression, suggesting modulation of key cancer pathways.

## Abstract

Punica granatum (pomegranate) peel is traditionally used for its antimicrobial and health-promoting properties in several cultures. Rich in polyphenols, the peel has attracted interest for its potential applications in treating infections and cancer, particularly in integrative approaches for immunocompromised patients.

Pomegranate peel extracts were prepared using solvents of increasing polarity, with emphasis on the ethyl acetate fraction (PPE-EA). A nano-formulated version (n-PPE-EA) was developed using a standard nano-encapsulation technique. Cytotoxic activity was evaluated in THP-1 human leukemia cells using MTT assay, flow cytometry, and biochemical analyses. Antimicrobial activity was assessed against Streptococcus pyogenes via agar diffusion. Gene expression of BCL2, PI3K, and CDK8 was measured to elucidate mechanisms of action.

Among all tested extracts, PPE-EA showed the strongest dual activity, reducing THP-1 cell viability by over 50% at 100 µg/mL and inhibiting S.
pyogenes with a 10.5 ± 1.1 mm zone. Nano-encapsulation enhanced both effects, reducing the IC₅₀ from 1.48 ± 0.03 µg/mL to 0.19 ± 0.01 µg/mL and increasing the bacterial inhibition zone to 15.6 ± 0.5 mm. n-PPE-EA induced apoptosis, cell cycle arrest, elevated catalase activity, and reduced malondialdehyde levels. It also downregulated BCL2, PI3K, and CDK8 expression.

The nano-formulated PPE-EA demonstrated potent cytotoxic and antimicrobial activities, with enhanced efficacy attributed to improved bioavailability and modulation of apoptotic and cell cycle pathways. These findings support its potential as a multifunctional therapeutic agent in integrative cancer care.

The online version contains supplementary material available at 10.1186/s12906-026-05291-9.

## Linked entities

- **Genes:** BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596], PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290], CDK8 (cyclin dependent kinase 8) [NCBI Gene 1024]
- **Diseases:** leukemia (MONDO:0004355)
- **Species:** Streptococcus pyogenes (taxon 1314)

## Full-text entities

- **Genes:** PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, CDK8 (cyclin dependent kinase 8) [NCBI Gene 1024] {aka IDDHBA, K35}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, CAT (catalase) [NCBI Gene 847]
- **Diseases:** Brain Heart Infusion (MESH:D000075662), necrosis (MESH:D009336), blood cancers (MESH:D019337), fungal (MESH:D009181), AML (MESH:D015470), solid (MESH:D018250), infectious disease (MESH:D003141), mitochondrial dysfunction (MESH:D028361), Leukemia (MESH:D007938), neutropenia (MESH:D009503), monocytic leukemia (MESH:D007951), cancer (MESH:D009369), opportunistic infections (MESH:D009894), infection (MESH:D007239), Cytotoxicity (MESH:D064420)
- **Chemicals:** kaempferol (MESH:C006552), CO2 (MESH:D002245), ellagitannins (MESH:D047348), polyphenol (MESH:D059808), Water (MESH:D014867), ampicillin (MESH:D000667), terpenoids (MESH:D013729), Apigenin (MESH:D047310), PE (MESH:C004544), naringenin (MESH:C005273), Squalene (MESH:D013185), myricetin (MESH:C040015), phenolic acids (MESH:C017616), lipid (MESH:D008055), ferulic acid (MESH:C004999), hydrogen (MESH:D006859), anthocyanins (MESH:D000872), alkaloids (MESH:D000470), caffeic acid (MESH:C040048), ellagic acid (MESH:D004610), TBARS (MESH:D017392), Butanol (MESH:D000440), luteolin (MESH:D047311), Tween 80 (MESH:D011136), ellagitannin (MESH:C013515), Epicatechin gallate (MESH:C062669), saponins (MESH:D012503), sinapic acid (MESH:C073734), DMSO (MESH:D004121), flavonoid (MESH:D005419), EE (MESH:D004997), EtOH (MESH:D000431), chlorogenic acid (MESH:D002726), methanol (MESH:D000432), punicalagin (MESH:C115642), Propidium Iodide (MESH:D011419), EA (MESH:C007650), H2O2 (MESH:D006861), BuOH (-), formazan (MESH:D005562), PTFE (MESH:D011138), gallic acid (MESH:D005707), penicillin (MESH:D010406), Campesterol (MESH:C021273), silica (MESH:D012822), DOX (MESH:D004317), Hex (MESH:D006586), formic acid (MESH:C030544), n (MESH:D009584), Quercetin (MESH:D011794), MTT (MESH:C070243), paclitaxel (MESH:D017239), vincristine (MESH:D014750), MDA (MESH:D008315), streptomycin (MESH:D013307), phytosterols (MESH:D010840), tannins (MESH:D013634), agar (MESH:D000362), acetonitrile (MESH:C032159)
- **Species:** Streptococcus pyogenes (species) [taxon 1314], Punica granatum (granado, species) [taxon 22663], Escherichia coli (E. coli, species) [taxon 562], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Staphylococcus aureus (species) [taxon 1280], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** TIB-202 — Sarcophilus harrisii (Tasmanian devil), Devil facial tumor disease 2, Cancer cell line (CVCL_LB80), HL-60 — Homo sapiens (Human), Adult acute myeloid leukemia with maturation, Cancer cell line (CVCL_0002), THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12955060/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12955060/full.md

## References

10 references — full list in the complete paper: https://tomesphere.com/paper/PMC12955060/full.md

---
Source: https://tomesphere.com/paper/PMC12955060